Plain-English translation of NCT06461897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a daily oral medication, works as well as or better than (an injected medication given every 2 to 4 weeks) for children ages 2 to under 12 with moderate to severe eczema. Both medications work by calming the skin inflammation that causes eczema. The trial will track how well each treatment works and what side effects children experience.
is already approved for eczema in children 12 and older, but doctors need to know if it's safe and effective for younger children. This medication offers a different approach (daily pills instead of injections) that some families might prefer, but it needs to be properly tested in this younger age group.
You likely qualify if…
You likely don't qualify if…
You would visit a hospital or clinic regularly over the course of the study (up to 160 weeks, or about 3 years). Your child would take either a daily oral medication (a tablet or liquid) or receive an injected medication every 2 to 4 weeks. At each visit, doctors will assess your child's skin, run blood tests, check for side effects, and ask about symptoms and quality of life through questionnaires. After the active treatment ends, there will be follow-up visits to monitor your child's health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States